PURPOSE: The aim of this assessment was to evaluate the safety and the efficacy of immunotherapy in pregnant women.
METHODS: The study population has been consisted of patients undergoing immunotherapy in the out-patient clinic in 2009. Self-prepared questionnaires were distributed among patients during routine visits. They included demographic information, the type of allergy and vaccines and the duration of IT. Separately patients and physicians evaluated the efficacy of treatment in respect of allergy symptoms from eyes, nose, bronchi/lungs and total efficacy in 5 degrees scale. They have also reported side effects after allergen vaccination and information related to pregnancy and labor in female questionnaires.
RESULTS: From 1189 patients receiving allergen vaccines 513 (43%) took part in the study, 197 (49%) from adults were women and 15 (7,6%) pregnant (one twice) during any time of the allergen immunotherapy course. All pregnant women were on maintenance therapy at the time they become pregnant. The duration of IT at the time of questionnaires collecting varied from 1 to 6 years. 10 women received pollen vaccines, 3-mites, 1-cat and 1-rabbit allergens. 14 pregnancies finished labors, all children born alive in good general state, one prematurely in 36 week, the other on time, none of them was hypotrophic. 8 from 14 pregnancies were finished by cesarean section. Two women were pregnant at time of study. Two pregnancies were complicated but none of them due to the immunotherapy. 5 from 15 women in the group of pregnant reported adverse events during IT (3 local and 2 systemic). None of the AE was serious and severe and none of the systemic AE occurred during pregnancy. In all cases the IT was assessed as effective by physicians and patients and the effectiveness were non inferior then in other women.
CONCLUSION: The IT in pregnant women seems to be safe and effective method when managed by experience staff.
CLINICAL IMPLICATIONS: In pregnent women the continuation of IT should be consider, but in any cases the conscious agreement must be obtained.
DISCLOSURE: Piotr Kuna, No Financial Disclosure Information; No Product/Research Disclosure Information